Phase 4 N=98 Use of Tranexamic Acid in Reduction Mammoplasty
Hematoma Postoperative · Venous Thromboembolism
Primary: Number of Breasts With Development of Hematoma — 2; 1 breasts
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=117 Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Primary: Number of Participants With Adverse Events — 6; 9; 6; 9 Participants
Phase 4 N=35 UNderstanding CONSciousness Connectedness and Intraoperative Unresponsiveness Study
Unconsciousness · Consciousness
Primary: Occipital Delta Power Spectral Density by Conscious State and Study Group. — 2.37; 1.62; 2.05; 2.1 log10(μV^2) — p=0.012
Phase 4 N=60 A Comparison of Proprietary Formulations of Oral Ketamine + Aspirin and Oral Ketamine Alone for Musculoskeletal Pain
Pain
Primary: Change in Pain Score at 60 Minutes — 2.18; 4.01 units on a scale
N/A N=20 A Randomized Placebo Controlled Pilot Study of Probiotic Supplementation in At-risk Pregnant Women
Iron-deficiency · Pregnancy, High Risk · Stress, Psychological
Primary: Mean Adherence to the Supplement Regimen — 67; 80 percentage of adherence
N/A N=20 Fertility Decision-Making in Youth and Young Adults
Transgender Adolescents & Young Adults
Primary: Change in Fertility-related Knowledge — 51.463; 67.073; 85.366; 93.171 score on a scale — p=<.001
N/A N=4,033 Are Sugar-Sweetened Beverage Information Labels Well-Targeted
Soft Drink Consumption · Sugar-sweetened Beverages · Information Labels
Primary: Willingness to Purchase Sugar-sweetened Beverage vs. Sugar-free Alternative — 0.06; -0.46; -0.39; -0.29 Dollars per 12-pack of soda — p=<0.001
Phase 2 N=29 Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
Metastatic Prostate Cancer · Pain
Primary: Percentage of Participants With 30% Decline in the Brief Pain Inventory (BPI) Worst Pain Item From Baseline to Week 8 — 11 Percentage of pts w/pain improvement
Phase 3 N=149 Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Parkinson's Disease
Primary: Total UPDRS I, II, III Scores — -5.97; -5.15; -1.31 units on a scale — p=0.0004
Phase 2 N=60 Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
Glioblastoma
Primary: Objective Response Rate (ORR) — 1; 3 Participants
Phase 2 N=47 Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19)
COVID-19
Primary: Number of Participants Requiring Mechanical Ventilation or Dying — 3; 3 Participants
Phase 4 N=64 Buffered Lidocaine in the Pediatric Dental Patient
Pediatric Dentistry
Primary: Patient Reported Pain Perception — 3.52; 3.48 units on a scale
Phase 2 N=31 Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer
Head and Neck Cancer
Primary: Overall Response — 28 Participants
Phase 2 N=460 TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE
Rheumatoid Arthritis
Primary: Change From Baseline (BL) in Disease Activity Score (DAS)28-C Reactive Protein (CRP) at Week 12 — -2.65; -2.35; -2.30; -2.20 Units on a scale — p=0.0158
N/A N=32 A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain
Bone Metastasis
Primary: Proportion of Responders — 18; 5; 8 Participants — p== 0.01